Abstract
H3K27M-mutant associated brainstem glioma (BSG) carries a very poor prognosis. We aimed to predict H3K27M mutation status by amide proton transfer-weighted (APTw) imaging and radiomic features. Eighty-one BSG patients with APTw imaging at 3T MR and known H3K27M status were retrospectively studied. APTw values (mean, median, and max) and radiomic features within manually delineated 3D tumor masks were extracted. Comparison of APTw measures between H3K27M-mutant and wildtype groups was conducted by two-sample Student's T/Mann-Whitney U test and receiver operating characteristic curve (ROC) analysis. H3K27M-mutant prediction using APTw-derived radiomics was conducted using a machine learning algorithm (support vector machine) in randomly selected train (n = 64) and test (n = 17) sets. Sensitivity analysis with additional random splits of train and test sets, 2D tumor masks, and other classifiers were conducted. Finally, a prospective cohort including 29 BSG patients was acquired for validation of the radiomics algorithm. BSG patients with H3K27M-mutant were younger and had higher max APTw values than those with wildtype. APTw-derived radiomic measures reflecting tumor heterogeneity could predict H3K27M mutation status with an accuracy of 0.88, sensitivity of 0.92, and specificity of 0.80 in the test set. Sensitivity analysis confirmed the predictive ability (accuracy range: 0.71-0.94). In the independent prospective validation cohort, the algorithm reached an accuracy of 0.86, sensitivity of 0.88, and specificity of 0.85 for predicting H3K27M-mutation status. BSG patients with H3K27M-mutant had higher max APTw values than those with wildtype. APTw-derived radiomics could accurately predict a H3K27M-mutant status in BSG patients.
Highlights
Brainstem gliomas (BSGs) are a heterogeneous group of tumors involving midbrain, pons and medulla
APTwderived radiomics could accurately predict a H3K27M-mutant status in BSG patients
We examined whether amide proton transfer weighted (APTw) and APTw-derived radiomic features could characterize the BSG metabolic heterogeneity and predict H3K27M mutation status
Summary
Brainstem gliomas (BSGs) are a heterogeneous group of tumors involving midbrain, pons and medulla. Genetic characterization is able to identify BSG patients with a poorer prognosis in those harboring a methionine in histone H3 at lysine 27 (H3K27) mutation [1], which causes an oncogene expression through global depletion of the repressive modification H3 lysine 27 trimethylation (H3K27me3) [2]. Invasive stereotactic biopsy can identify the H3K27M-mutant status with a high sensitivity and specificity, but carries a significant risk of complication [4]. Noninvasive conventional magnetic resonance imaging (MRI) is able to depict BSG location, morphology, diffusion, perfusion and metabolic characteristics, but is unable to predict genetic mutation status with insufficient specificity (
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: European Journal of Nuclear Medicine and Molecular Imaging
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.